DiaSorin S.p.A.
DSRLFOTCHealthcare● Active
$84.10
+$0.00(+0.00%)
Market Cap$4.5B
P/E Ratio—
52W High$112.3
52W Low$66.5
DiaSorin S.p.A. (DSRLF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DSRLF · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 20, 2026EPS Actual
$1.06
Revenue
$0.68B
Est. $0.71B · -5.2%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 20, 2026
After Market Close
▼ Miss Revenue
DSRLF reports quarterly as a OTC-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | — | — | — | — | $0.36B | — |
| ◌ Q2 FY2026 | May 8, 2026 | — | — | — | — | $0.34B | — |
| — Q1 FY2026 | Mar 20, 2026 | — | $1.06 | — | $0.68B | $0.71B | -5.2% |
| — Q3 FY2025 | Jul 31, 2025 | — | $1.03 | — | $0.36B | $0.34B | +5.9% |
| ▼ Q1 FY2025 | Mar 13, 2025 | $2.21 | $1.06 | -52.0% | $0.34B | $0.35B | -1.4% |
| — Q4 FY2024 | Dec 31, 2024 | — | $0.91 | — | $0.32B | — | — |
| — Q4 FY2024 | Nov 5, 2024 | — | $0.93 | — | $0.31B | $0.34B | -7.2% |
| — Q3 FY2024 | Jul 29, 2024 | — | $1.01 | — | $0.32B | $0.63B | -48.5% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 20, 2026
EPS Actual
$1.06
EPS Est.
—
EPS Surpr.
—
Revenue
$0.68B
Q3 FY2025
Jul 31, 2025
EPS Actual
$1.03
EPS Est.
—
EPS Surpr.
—
Revenue
$0.36B
Q1 FY2025
Mar 13, 2025Miss
EPS Actual
$1.06
EPS Est.
$2.21
EPS Surpr.
-52.0%
Revenue
$0.34B
Q4 FY2024
Dec 31, 2024
EPS Actual
$0.91
EPS Est.
—
EPS Surpr.
—
Revenue
$0.32B
Q4 FY2024
Nov 5, 2024
EPS Actual
$0.93
EPS Est.
—
EPS Surpr.
—
Revenue
$0.31B
Q3 FY2024
Jul 29, 2024
EPS Actual
$1.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.32B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2026 | $2.20 | $2.22 | $2.23 | 1 |
| Q3 FY2026 | $2.19 | $2.21 | $2.22 | 1 |
| Q2 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $0.5B | $0.5B | $0.5B | 1 |
| Q1 FY2027 | $0.5B | $0.5B | $0.5B | 1 |
| Q4 FY2026 | $0.5B | $0.5B | $0.6B | 1 |
| Q3 FY2026 | $0.5B | $0.5B | $0.5B | 2 |
| Q2 FY2026 | $0.5B | $0.5B | $0.5B | 2 |
| Q1 FY2026 | $0.5B | $0.5B | $0.6B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q1 FY2026 | Mar 20, 2026 | — | $81.15 | $70.76 | -12.80% |
| — Q3 FY2025 | Jul 31, 2025 | — | $107.68 | $107.68 | +0.00% |
| ▼ Q1 FY2025 | Mar 13, 2025 | -52.0% | $109.60 | $109.60 | +0.00% |
| — Q4 FY2024 | Dec 31, 2024 | — | $106.85 | $106.85 | +0.00% |
| — Q4 FY2024 | Nov 5, 2024 | — | $107.88 | $107.88 | +0.00% |
| — Q3 FY2024 | Jul 29, 2024 | — | $99.86 | $99.86 | +0.00% |
| — Q2 FY2024 | May 10, 2024 | — | $107.40 | $107.40 | +0.00% |
| — Q4 FY2023 | Dec 30, 2023 | — | $99.78 | $99.78 | +0.00% |
Q1 FY2026-12.80%
Report Date
Mar 20, 2026
EPS Beat/Miss
—
Price Before
$81.15
Price After
$70.76
Q3 FY2025+0.00%
Report Date
Jul 31, 2025
EPS Beat/Miss
—
Price Before
$107.68
Price After
$107.68
Q1 FY2025+0.00%
Report Date
Mar 13, 2025
EPS Beat/Miss
-52.0%
Price Before
$109.60
Price After
$109.60
Q4 FY2024+0.00%
Report Date
Dec 31, 2024
EPS Beat/Miss
—
Price Before
$106.85
Price After
$106.85
Q4 FY2024+0.00%
Report Date
Nov 5, 2024
EPS Beat/Miss
—
Price Before
$107.88
Price After
$107.88
Q3 FY2024+0.00%
Report Date
Jul 29, 2024
EPS Beat/Miss
—
Price Before
$99.86
Price After
$99.86
Q2 FY2024+0.00%
Report Date
May 10, 2024
EPS Beat/Miss
—
Price Before
$107.40
Price After
$107.40
Q4 FY2023+0.00%
Report Date
Dec 30, 2023
EPS Beat/Miss
—
Price Before
$99.78
Price After
$99.78
Avg Miss Reaction+0.00%
Beat Rate0 / 8 quarters
Largest Move-12.80% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DSRLF ends December
DiaSorin S.p.A. (DSRLF) most recently reported earnings on March 20, 2026 for Q1 FY2026, posting EPS of $1.06 (in line with the analyst consensus of —). The next DSRLF earnings date is expected around September 1, 2026.
Each quarter, investors track DSRLF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DSRLF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DSRLF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DSRLF earnings · 4 questionsDiaSorin S.p.A.'s next earnings report is expected around September 1, 2026. DSRLF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DSRLF historically reports after market close (AMC).
DSRLF earnings datewhen is DSRLF earningsDSRLF next earnings datewhen does DSRLF report earningsDSRLF earnings calendar
▸ Source: FMP · DiaSorin S.p.A. SEC filings · US GAAP · DiaSorin S.p.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026